Duke Health to Host Continuing Education Conference on Bispecifics and ADCs

October 10, 2026 - 18:02

Duke Health has announced a new continuing education conference focused on the rapidly evolving field of bispecific antibodies, antibody drug conjugates, and other emerging cancer therapies. The event aims to bring together oncologists, researchers, and healthcare professionals seeking to stay current with the latest developments in targeted treatment approaches.

The conference will feature presentations from leading experts in the field, including Charlie Rudin, who is known for his work in cancer research and treatment innovation. Laura Alder is among the organizers involved in coordinating the program, which is designed to address both the scientific foundations and practical clinical applications of these therapies.

Bispecific antibodies and antibody drug conjugates represent two of the most promising areas in oncology. Bispecifics work by binding to two different targets at once, which can help the immune system better recognize and attack cancer cells. ADCs, meanwhile, deliver cytotoxic drugs directly to tumor cells, potentially reducing damage to healthy tissue.

The continuing education format is intended to help clinicians understand how these treatments fit into current practice and what the future may hold. Sessions will likely cover mechanism of action, patient selection, management of side effects, and ongoing clinical trials. Attendees can expect a mix of lectures, case discussions, and opportunities to engage with peers and faculty.

As the oncology landscape shifts toward more personalized and precise therapies, events like this provide a structured way for providers to keep pace. Duke Health's involvement signals a commitment to advancing education in a field where new data emerges quickly. Registration details and a full agenda are expected to be released in the coming weeks.